Stand Up 2 HPV: Improving HPV Vaccination Rates
This study, called "Stand Up 2 HPV," is looking for ways to increase vaccination rates for the Human Papillomavirus (HPV) in children aged 9 to 17. HPV can cause serious cancers, but many young people are not vaccinated. This study will test two approaches: training healthcare staff (providers and nurses) on how to talk about HPV vaccination, and training them to use "standing orders." Standing orders are written instructions that allow nurses to give vaccines without needing a doctor's specific approval for each patient. The goal is to see if these methods lead to more opportunities for patients to receive the HPV vaccine over a 12-month period. You can join if you are an active patient in an AHP practice and are between 9 and 17 years old. The study is not recruiting from practices that already have very high HPV vaccination rates or very few eligible 11-12 year olds.
- Study design
- This is an interventional study aiming to enroll 16,000 participants. It is not specified if it is randomized or blinded.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, patient-level captured opportunities for HPV vaccination, is measured at a 12-month intervention period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Patient-Level Captured Opportunities for HPV Vaccination12-month intervention period
The percentage of HPV vaccine eligible patients, aged 9-17, with a practice visit during the specified timeframe of interest who receive \>=1 HPV vaccination.